A lot's happened since your Dec19 post. Merck has partnered with Qbiotics in a melanoma project. Qbiotics anti-cancer vet drug Stelfonta is on sale. Human trials Phase1/11 are ticking all boxes. Merck wants to put its market-leading keytruda drug up against Qbiotics' tigilanol tiglate (TT). On its own TT Phase1/11 human trials using the bare minimum dose for safety testing it positively affected 27% and completely worked (you have to be careful how to put this) in 18% of cases. The partnership wants to know do the numbers get higher when combined with keytruda. What's the share price now?
